Osama Mehanna

Prof. Osama Mehanna

Al Azhar University, Cairo, Al Qāhirah, Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OMOsama Mehanna
Osama Mehanna
BEBasem H. Elesawy
Basem H. Elesawy
AAAhmad Askary
Ahmad Askary
MHMohamed Gaber Mohamed Hassan
Mohamed Gaber Mohamed Hassan
WAWalid Mostafa Ahmed
Walid Mostafa Ahmed
MKMohamed Mansour Khalifa
Mohamed Mansour Khalifa
Background: Diabetic neuropathy (DN) is the most prevalent complication of diabetes, impacting up to 60% of people with diabetes. It is characterized by distal symmetrical loss of sensory function in the lower extremities, presenting with spontaneous excruciating neuropathic pain, hyperalgesia, and allodynia that impairs quality of life. The current work aims to evaluate the neuroprotective potential of naringin (a citrus flavonoid) and examine its ability to improve STZ-induced diabetic neuropathic pain by investigating its hypoglycemic, hypolipidemic, antioxidant, and anti-inflammatory effects. Methods: out of 40 adult male Sprague-Dawley rats, diabetes was induced in 30 rats by a single injection of STZ (45 mg/kg dissolved in citrate buffer). Ten days after induction of diabetes, rats were divided into four groups (10/group): normal control, diabetic control, naringin-treated diabetic rats, and glimepiride-treated diabetic rats as a positive control group. At the end of the experiment, serum and brain tissue samples will be collected then the hypoglycemic, lipid-lowering, antioxidant, and anti-inflammatory effects of naringin will be assessed and compared with that of glimepiride (a standard antidiabetic drug). Hyperalgesia and the effect of the studied drugs on it will also be evaluated by observing pain related behaviors in diabetic rats using hot plate, tail immersion, and mechanical sensitivity (von Frey) tests. Results: Significant increase in the serum levels of glucose, tri-glyceride (TG), total cholesterol (t‐cholesterol), low‐density lipoprotein‐cholesterol (LDL-C), and nitric oxide (NO), with a concomitant decrease in body weight (BW), plasma insulin and high‐density lipoprotein‐cholesterol (HDL-C) were observed in diabetic rats. Also, the brain level of malondialdehyde (MDA) was increased, while that of reduced glutathione (GSH), glutathione peroxidase (Gpx), superoxide dismutase (SOD), and catalase (CAT) were markedly decreased. Furthermore, diabetic rats showed a marked increase in plasma levels of proinflammatory cytokines including interleukin‐6 (IL-6) and tumor necrosis factor‐α (TNF-α). Moreover, hot plate, tail immersion, and von Frey tests revealed hyperalgesia in diabetic rats. Treatment with naringin and glimepiride reduced pain hypersensitivity, restored body weight and nearly normalized the altered biochemical parameters, more significantly with naringin than with glimepiride. Conclusion: These results may highlight the potential effects of naringin as a therapeutic strategy for diabetes and its complications including peripheral neuropathy.